IDEAS home Printed from https://ideas.repec.org/e/pmc184.html
   My authors  Follow this author

Christopher Joseph McCabe

Personal Details

First Name:Christopher
Middle Name:Joseph
Last Name:McCabe
Suffix:
RePEc Short-ID:pmc184
[This author has chosen not to make the email address public]
http://www.leeds.ac.uk/lihs/auhe/People/McCabe_C.html

Affiliation

(70%) University of Alberta, Faculty of Medicine and Dentistry

http://www.med.ualberta.ca/
Edmonton, Alberta

(15%) Academic Unit of Health Economics
Leeds Institute of Health Sciences
University of Leeds

Leeds, United Kingdom
http://medhealth.leeds.ac.uk/auhe

: Worsley Building, Level 11, Clarendon Way, LEEDS LS2 9NL
+44 (0) 113 343 3470

RePEc:edi:heleeuk (more details at EDIRC)

(15%) Department of Economics
University of Alberta

Edmonton, Canada
http://economics.ualberta.ca/

: (780) 492-3406
(780) 492-3300
8-14 HM Tory, Edmonton, Alberta, T6G 2H4
RePEc:edi:deualca (more details at EDIRC)

Research output

as
Jump to: Working papers Articles

Working papers

  1. Peter S Hall & Christopher McCabe & Richard Edlin & Julia Brown & Claire Hulme & David Cameron, 2013. "Evidence needs for licensing and reimbursement," Working Papers 1301, Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds.
  2. Richard Edlin & Christopher McCabe & David Meads, 2013. "Assignment errors and the valuation of EQ-5D health states-do responses mean what we think they mean?," Working Papers 1304, Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds.
  3. Christopher McCabe & Paul Baxter & Roberta Longo & Peter Hall & Jenny Hewison & Mehran Afshar & Geoff Hall, 2013. "Methods for Identifying the Cost-effective Case Definition Cut-off for Sequential Monitoring Tests: an Extension of Phelps and Mushlin," Working Papers 1303, Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds.
  4. Samer A Kharroubi & Richard Edlin & David Meads & Chantelle Browne & Julia Brown & Christopher McCabe, 2013. "Use of Bayesian Markov Chain Monte Carlo Methods to Estimate EQ-5D Utility Scores from Eortic QLQ Data in Myeloma for Use in Cost effectiveness Analysis," Working Papers 1308, Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds.
  5. Christopher McCabe & Richard Edlin & Peter Hall & Klemens Wallner, 2013. "Leasing health technologies- an affordable and effective reimbursement strategy for innovative technologies?," Working Papers 1302, Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds.
  6. Christopher McCabe & Richard Edlin & Peter Hall, 2012. "Navigating time and uncertainty in health technology appraisal: would a map help?," Working Papers 1201, Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds.
  7. Yemi Oluboyede & Sandy Tubeuf & Chris McCabe, 2011. "Measuring health outcomes of adolescents: report from a pilot study," Working Papers 1102, Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds.
  8. Chantelle Browne & Roberta Longo & Richard Edlin & Jennifer Roberts & Christopher McCabe, 2011. "Challenges in modelling censored health state preference data: Explorations with the EQ-5D and HUI2," Working Papers 1103, Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds.
  9. Peter S Hall & Richard Edlin & Samer Kharroubi & Walter Gregory & Christopher McCabe, 2011. "Expected Net Present Value of Sample Information: from burden to investment," Working Papers 1101, Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds.
  10. Richard Edlin & Roberta Longo & Christopher McCabe, 2010. "Supra-states and censoring in health utility modelling: an examination of their importance in the EQ-5D tariff," Working Papers 1002, Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds.
  11. Richard Edlin & Christopher McCabe & Jeff Round & Judy Wright & Karl Claxton & Mark Sculpher & Richard Cookson, 2010. "Understanding Harris’ understanding of CEA: is cost effective resource allocation undone?," Working Papers 1005, Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds.
  12. Peter Hall & Claire Hulme & Christopher McCabe & Yemi Oluboyede & Jeff Round & David A Cameron, 2010. "Updated cost-effectiveness analysis of trastuzumab for early breast cancer:A UK perspective considering long-term toxicity and pattern of recurrence," Working Papers 1001, Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds.
  13. McCabe, C & Claxton, K & Culyer, AJ, 2008. "The NICE Cost-Effectiveness Threshold: What it is and What that Means," MPRA Paper 26466, University Library of Munich, Germany.
  14. Karl Claxton & Simon Eggington & Laura Ginnelly & Susan Griffin & Christopher McCabe & Zoe Philips & Paul Tappenden & Alan Wailoo, 2005. "A Pilot Study of Value of Information Analysis to Support Research Recommendations for the National Institute for Health and Clinical Excellence," Working Papers 004cherp, Centre for Health Economics, University of York.
  15. McCabe, C & Brazier, J & Gilks, P & Tsuchiya, A & Roberts, J & O'Hagan, A & Stevens, K, 2004. "Estimating population cardinal health state valuation models from individual ordinal (rank) health state preference data," MPRA Paper 29759, University Library of Munich, Germany.
  16. McCabe, C & Stevens, K & Roberts, J & Brazier, JE, 2003. "Health state values for the HUI 2 descriptive system: results from a UK survey," MPRA Paper 29744, University Library of Munich, Germany.

Articles

  1. Christopher McCabe & Richard Edlin & David Meads & Chantelle Brown & Samer Kharroubi, 2013. "Constructing Indirect Utility Models: Some Observations on the Principles and Practice of Mapping to Obtain Health State Utilities," PharmacoEconomics, Springer, vol. 31(8), pages 635-641, August.
  2. Yemi Oluboyede & Sandy Tubeuf & Chris McCabe, 2013. "Measuring health outcomes of adolescents: report from a pilot study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 11-19, February.
  3. Christopher McCabe & Richard Edlin & Peter Hall, 2013. "Navigating Time and Uncertainty in Health Technology Appraisal: Would a Map Help?," PharmacoEconomics, Springer, vol. 31(9), pages 731-737, September.
  4. Peter Hall & Christopher McCabe, 2013. "What Evidence Is There for the Reimbursement of Personalised Medicine?," PharmacoEconomics, Springer, vol. 31(3), pages 181-183, March.
  5. Musal, R. Muzaffer & Soyer, Refik & McCabe, Christopher & Kharroubi, Samer A., 2012. "Estimating the population utility function: A parametric Bayesian approach," European Journal of Operational Research, Elsevier, vol. 218(2), pages 538-547.
  6. Stevens, Katherine & McCabe, Christopher & Brazier, John & Roberts, Jennifer, 2007. "Multi-attribute utility function or statistical inference models: A comparison of health state valuation models using the HUI2 health state classification system," Journal of Health Economics, Elsevier, vol. 26(5), pages 992-1002, September.
  7. John Brazier & Christopher McCabe, 2007. "Is there a case for using visual analogue scale valuations in CUA' by Parkin and Devlin a response: 'yes there is a case, but what does it add to ordinal data?," Health Economics, John Wiley & Sons, Ltd., vol. 16(6), pages 645-647.
  8. Katherine Stevens & Christopher McCabe & John Brazier, 2007. "Response to Shmueli," Health Economics, John Wiley & Sons, Ltd., vol. 16(7), pages 759-761.
  9. McCabe, Christopher & Brazier, John & Gilks, Peter & Tsuchiya, Aki & Roberts, Jennifer & O'Hagan, Anthony & Stevens, Katherine, 2006. "Using rank data to estimate health state utility models," Journal of Health Economics, Elsevier, vol. 25(3), pages 418-431, May.
  10. Mark J. Sculpher & Karl Claxton & Mike Drummond & Chris McCabe, 2006. "Whither trial-based economic evaluation for health care decision making?," Health Economics, John Wiley & Sons, Ltd., vol. 15(7), pages 677-687.
  11. Christopher McCabe & Katherine Stevens & Jennifer Roberts & John Brazier, 2006. "Erratum to 'Health state values for the health utilities index mark 2 descriptive system: results from a UK valuation survey' Health Economics 2005; 14 (3): 231-244," Health Economics, John Wiley & Sons, Ltd., vol. 15(7), pages 761-761.
  12. Karl Claxton & Mark Sculpher & Anthony Culyer & Chris McCabe & Andrew Briggs & Ron Akehurst & Martin Buxton & John Brazier, 2006. "Discounting and cost-effectiveness in NICE - stepping back to sort out a confusion," Health Economics, John Wiley & Sons, Ltd., vol. 15(1), pages 1-4.
  13. Katherine J. Stevens & Christopher J. McCabe & John E. Brazier, 2006. "Mapping between Visual Analogue Scale and Standard Gamble data; results from the UK Health Utilities Index 2 valuation survey," Health Economics, John Wiley & Sons, Ltd., vol. 15(5), pages 527-533.
  14. Christopher McCabe & Katherine Stevens & Jennifer Roberts & John Brazier, 2005. "Health state values for the HUI 2 descriptive system: results from a UK survey," Health Economics, John Wiley & Sons, Ltd., vol. 14(3), pages 231-244.
  15. Karl Claxton & Mark Sculpher & Chris McCabe & Andrew Briggs & Ron Akehurst & Martin Buxton & John Brazier & Tony O'Hagan, 2005. "Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra," Health Economics, John Wiley & Sons, Ltd., vol. 14(4), pages 339-347.

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Working papers

  1. Christopher McCabe & Richard Edlin & Peter Hall & Klemens Wallner, 2013. "Leasing health technologies- an affordable and effective reimbursement strategy for innovative technologies?," Working Papers 1302, Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds.

    Cited by:

    1. Aidan Hollis, 2016. "Sustainable Financing of Innovative Therapies: A Review of Approaches," PharmacoEconomics, Springer, vol. 34(10), pages 971-980, October.
    2. Michael Drummond, 2015. "When do performance-based risk-sharing arrangements make sense?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(6), pages 569-571, July.

  2. Christopher McCabe & Richard Edlin & Peter Hall, 2012. "Navigating time and uncertainty in health technology appraisal: would a map help?," Working Papers 1201, Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds.

    Cited by:

    1. Christopher McCabe & Richard Edlin & Peter Hall & Klemens Wallner, 2013. "Leasing health technologies- an affordable and effective reimbursement strategy for innovative technologies?," Working Papers 1302, Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds.
    2. James O’Mahony & Anthony Newall & Joost Rosmalen, 2015. "Dealing with Time in Health Economic Evaluation: Methodological Issues and Recommendations for Practice," PharmacoEconomics, Springer, vol. 33(12), pages 1255-1268, December.

  3. Peter S Hall & Richard Edlin & Samer Kharroubi & Walter Gregory & Christopher McCabe, 2011. "Expected Net Present Value of Sample Information: from burden to investment," Working Papers 1101, Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds.

    Cited by:

    1. Christopher McCabe & Richard Edlin & Peter Hall, 2013. "Navigating Time and Uncertainty in Health Technology Appraisal: Would a Map Help?," PharmacoEconomics, Springer, vol. 31(9), pages 731-737, September.

  4. Peter Hall & Claire Hulme & Christopher McCabe & Yemi Oluboyede & Jeff Round & David A Cameron, 2010. "Updated cost-effectiveness analysis of trastuzumab for early breast cancer:A UK perspective considering long-term toxicity and pattern of recurrence," Working Papers 1001, Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds.

    Cited by:

    1. Christopher McCabe & Richard Edlin & Peter Hall & Klemens Wallner, 2013. "Leasing health technologies- an affordable and effective reimbursement strategy for innovative technologies?," Working Papers 1302, Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds.
    2. Lotte Steuten & Gijs Wetering & Karin Groothuis-Oudshoorn & Valesca Retèl, 2013. "A Systematic and Critical Review of the Evolving Methods and Applications of Value of Information in Academia and Practice," PharmacoEconomics, Springer, vol. 31(1), pages 25-48, January.
    3. Christopher McCabe & Richard Edlin & Peter Hall, 2013. "Navigating Time and Uncertainty in Health Technology Appraisal: Would a Map Help?," PharmacoEconomics, Springer, vol. 31(9), pages 731-737, September.

  5. McCabe, C & Claxton, K & Culyer, AJ, 2008. "The NICE Cost-Effectiveness Threshold: What it is and What that Means," MPRA Paper 26466, University Library of Munich, Germany.

    Cited by:

    1. Christopher McCabe & Mike Paulden & James O'Mahony & Richard Edlin & Anthony Culyer, 2014. "Life at a premium: considering an end-of-life premium in Value Based Reimbursement," Working Papers 1407, Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds.
    2. Zanfina Ademi & Kumar Pasupathi & Danny Liew, 2017. "Clinical and Cost Effectiveness of Apixaban Compared to Aspirin in Patients with Atrial Fibrillation: An Australian Perspective," Applied Health Economics and Health Policy, Springer, vol. 15(3), pages 363-374, June.
    3. Refoios Camejo, Rodrigo & McGrath, Clare & Herings, Ron, 2011. "A dynamic perspective on pharmaceutical competition, drug development and cost effectiveness," Health Policy, Elsevier, vol. 100(1), pages 18-24, April.
    4. Christopher McCabe & Richard Edlin & Peter Hall & Klemens Wallner, 2013. "Leasing health technologies- an affordable and effective reimbursement strategy for innovative technologies?," Working Papers 1302, Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds.
    5. Carlos K. H. Wong & Brian H. H. Lang & Vivian Y. W. Guo & Cindy L. K. Lam, 2016. "Possible Impact of Incremental Cost-Effectiveness Ratio (ICER) on Decision Making for Cancer Screening in Hong Kong: A Systematic Review," Applied Health Economics and Health Policy, Springer, vol. 14(6), pages 647-657, December.
    6. Katharina Schremser & Wolf Rogowski & Sigrid Adler-Reichel & Amanda Tufman & Rudolf Huber & Björn Stollenwerk, 2015. "Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany," PharmacoEconomics, Springer, vol. 33(11), pages 1215-1228, November.
    7. Mike Paulden & Christopher McCabe & Jonathan Karnon, 2014. "Achieving Allocative Efficiency in Healthcare: Nice in Theory, not so NICE in Practice?," PharmacoEconomics, Springer, vol. 32(4), pages 315-318, April.
    8. Thomas Delea & Paul Tappenden & Oleg Sofrygin & Dominy Browning & Mayur Amonkar & Jon Karnon & Mel Walker & David Cameron, 2012. "Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(5), pages 589-603, October.
    9. John Vernon & Robert Goldberg & Joseph Golec, 2009. "Economic Evaluation and Cost-Effectiveness Thresholds," PharmacoEconomics, Springer, vol. 27(10), pages 797-806, October.
    10. Lionel Perrier & Anne Lefranc & Philippe Quittet & Philippe Moreau & Carole Siani & Hervé Ghesquières & Fabrice Jardin & Bertrand Favier & Norbert Ifrah & Séverine Lissandre & David Pérol & Catherine , 2011. "Cost-effectiveness of Pegfilgrastim versus Filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma," Post-Print halshs-00628829, HAL.
    11. J. Jaime Caro & Erik Nord & Uwe Siebert & Alistair McGuire & Maurice McGregor & David Henry & Gérard de Pouvourville & Vincenzo Atella & Peter Kolominsky-Rabas, 2010. "The efficiency frontier approach to economic evaluation of health-care interventions," Health Economics, John Wiley & Sons, Ltd., vol. 19(10), pages 1117-1127.
    12. Marieke Krol & Jocé Papenburg & Siok Swan Tan & Werner Brouwer & Leona Hakkaart, 2016. "A noticeable difference? Productivity costs related to paid and unpaid work in economic evaluations on expensive drugs," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(4), pages 391-402, May.
    13. Wildman, John & McMeekin, Peter & Grieve, Eleanor & Briggs, Andrew, 2016. "Economic evaluation of integrated new technologies for health and social care: Suggestions for policy makers, users and evaluators," Social Science & Medicine, Elsevier, vol. 169(C), pages 141-148.
    14. Irz, Xavier & Leroy, Pascal & Réquillart, Vincent & Soler, Louis-Georges, 2016. "Welfare and sustainability effects of dietary recommendations," Ecological Economics, Elsevier, vol. 130(C), pages 139-155.
    15. Klingler, Corinna & Shah, Sara M.B. & Barron, Anthony J.G. & Wright, John S.F., 2013. "Regulatory space and the contextual mediation of common functional pressures: Analyzing the factors that led to the German Efficiency Frontier approach," Health Policy, Elsevier, vol. 109(3), pages 270-280.
    16. A. Newall & M. Jit & R. Hutubessy, 2014. "Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines," PharmacoEconomics, Springer, vol. 32(6), pages 525-531, June.
    17. Karl Claxton & Simon Walker & Steven Palmer & Mark Sculpher, 2010. "Appropriate Perspectives for Health Care Decisions," Working Papers 054cherp, Centre for Health Economics, University of York.
    18. Liran Einav & Amy Finkelstein & Heidi Williams, 2016. "Paying on the Margin for Medical Care: Evidence from Breast Cancer Treatments," American Economic Journal: Economic Policy, American Economic Association, vol. 8(1), pages 52-79, February.
    19. Emma Cowles & Grace Marsden & Amanda Cole & Nancy Devlin, 2017. "A Review of NICE Methods and Processes Across Health Technology Assessment Programmes: Why the Differences and What is the Impact?," Applied Health Economics and Health Policy, Springer, vol. 15(4), pages 469-477, August.
    20. Roland Diel & Niklas Lampenius & Albert Nienhaus, 2015. "Cost Effectiveness of Preventive Treatment for Tuberculosis in Special High-Risk Populations," PharmacoEconomics, Springer, vol. 33(8), pages 783-809, August.
    21. Jinsong Geng & Hao Yu & Yiwei Mao & Peng Zhang & Yingyao Chen, 2015. "Cost Effectiveness of Dipeptidyl Peptidase-4 Inhibitors for Type 2 Diabetes," PharmacoEconomics, Springer, vol. 33(6), pages 581-597, June.
    22. Stefano Capri & Rosella Levaggi, 2011. "Shifting the risk in pricing and reimbursement schemes? A model of risk-sharing agreements for innovative drugs," DEP - series of economic working papers 2/2011, University of Genoa, Research Doctorate in Public Economics.
    23. Hossein Haji Ali Afzali & Jonathan Karnon & Mark Sculpher, 2016. "Should the Lambda (λ) Remain Silent?," PharmacoEconomics, Springer, vol. 34(4), pages 323-329, April.
    24. Andrew Willan & Simon Eckermann, 2012. "Value of Information and Pricing New Healthcare Interventions," PharmacoEconomics, Springer, vol. 30(6), pages 447-459, June.
    25. Brown, Vicki & Diomedi, Belen Zapata & Moodie, Marj & Veerman, J. Lennert & Carter, Rob, 2016. "A systematic review of economic analyses of active transport interventions that include physical activity benefits," Transport Policy, Elsevier, vol. 45(C), pages 190-208.
    26. László Gulácsi & Alexandru Rotar & Maciej Niewada & Olga Löblová & Fanni Rencz & Guenka Petrova & Imre Boncz & Niek Klazinga, 2014. "Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 13-25, May.
    27. Rachel Elliott & Koen Putman & Matthew Franklin & Lieven Annemans & Nick Verhaeghe & Martin Eden & Jasdeep Hayre & Sarah Rodgers & Aziz Sheikh & Anthony Avery, 2014. "Cost Effectiveness of a Pharmacist-Led Information Technology Intervention for Reducing Rates of Clinically Important Errors in Medicines Management in General Practices (PINCER)," PharmacoEconomics, Springer, vol. 32(6), pages 573-590, June.
    28. F. Tomini & F. Prinzen & A. D. I. Asselt, 2016. "A review of economic evaluation models for cardiac resynchronization therapy with implantable cardioverter defibrillators in patients with heart failure," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(9), pages 1159-1172, December.
    29. Christopher McCabe & Paul Baxter & Roberta Longo & Peter Hall & Jenny Hewison & Mehran Afshar & Geoff Hall, 2013. "Methods for Identifying the Cost-effective Case Definition Cut-off for Sequential Monitoring Tests: an Extension of Phelps and Mushlin," Working Papers 1303, Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds.
    30. L. Gulácsi & M. Péntek, 2014. "HTA in Central and Eastern European countries; the 2001: A Space Odyssey and efficiency gain," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(7), pages 675-680, September.
    31. Simon Eckermann & Brita Pekarsky, 2014. "Can the Real Opportunity Cost Stand Up: Displaced Services, the Straw Man Outside the Room," PharmacoEconomics, Springer, vol. 32(4), pages 319-325, April.
    32. Martin Hoyle, 2011. "Accounting for the Drug Life Cycle and Future Drug Prices in Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 29(1), pages 1-15, January.
    33. Mike Paulden & Karl Claxton, 2009. "Budget allocation and the revealed social rate of time preference for health," Working Papers 053cherp, Centre for Health Economics, University of York.
    34. Mark Sculpher & Karl Claxton, 2012. "Real Economics Needs to Reflect Real Decisions," PharmacoEconomics, Springer, vol. 30(2), pages 133-136, February.
    35. Roberta Longo & Paul Baxter & Peter Hall & Jenny Hewison & Mehran Afshar & Geoff Hall & Christopher McCabe, 2014. "Methods for Identifying the Cost-effective Case Definition Cut-Off for Sequential Monitoring Tests: An Extension of Phelps and Mushlin," PharmacoEconomics, Springer, vol. 32(4), pages 327-334, April.
    36. Mike Paulden & Tania Stafinski & Devidas Menon & Christopher McCabe, 2015. "Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework," PharmacoEconomics, Springer, vol. 33(3), pages 255-269, March.
    37. Mark Sculpher & Karl Claxton, 2010. "Sins of omission and obfuscation: IQWIG's guidelines on economic evaluation methods," Health Economics, John Wiley & Sons, Ltd., vol. 19(10), pages 1132-1136.
    38. Daniel Howdon & James Lomas, 2017. "Pricing implications of non-marginal budgetary impacts in health technology assessment: a conceptual model," Working Papers 148cherp, Centre for Health Economics, University of York.
    39. Grupo de Economía de la Salud & Jairo Humberto Restrepo, 2012. "Economía de las enfermedades crónicas no transmisibles: Implicaciones para Colombia," OBSERVATORIO SEGURIDAD SOCIAL 015579, GRUPO DE ECONOMÍA DE LA SALUD.
    40. Simon Eckermann, 2015. "Kinky Thresholds Revisited: Opportunity Costs Differ in the NE and SW Quadrants," Applied Health Economics and Health Policy, Springer, vol. 13(1), pages 7-13, February.
    41. Jamie Elvidge & Ash Bullement & Anthony J. Hatswell, 2016. "Cost Effectiveness of Characterised Chondrocyte Implantation for Treatment of Cartilage Defects of the Knee in the UK," PharmacoEconomics, Springer, vol. 34(11), pages 1145-1159, November.
    42. Karl Claxton & Stephen Palmer & Louise Longworth & Laura Bojke & Susan Griffin & Claire McKenna & Marta Soares & Eldon Spackman & Jihee Youn, 2011. "Uncertainty, evidence and irrecoverable costs: Informing approval, pricing and research decisions for health technologies," Working Papers 069cherp, Centre for Health Economics, University of York.
    43. Fischer, Katharina Elisabeth, 2012. "A systematic review of coverage decision-making on health technologies—Evidence from the real world," Health Policy, Elsevier, vol. 107(2), pages 218-230.

  6. Karl Claxton & Simon Eggington & Laura Ginnelly & Susan Griffin & Christopher McCabe & Zoe Philips & Paul Tappenden & Alan Wailoo, 2005. "A Pilot Study of Value of Information Analysis to Support Research Recommendations for the National Institute for Health and Clinical Excellence," Working Papers 004cherp, Centre for Health Economics, University of York.

    Cited by:

    1. Elisabeth Fenwick & Karl Claxton & Mark Sculpher, 2005. "The value of implementation and the value of information: combined and uneven development," Working Papers 005cherp, Centre for Health Economics, University of York.
    2. Bas Groot Koerkamp & M. G. Myriam Hunink & Theo Stijnen & Milton C. Weinstein, 2006. "Identifying key parameters in cost-effectiveness analysis using value of information: a comparison of methods," Health Economics, John Wiley & Sons, Ltd., vol. 15(4), pages 383-392.
    3. Felipa, de Mello-Sampayo, 2014. "The Timing and Probability of Switching to Second-line Regimen - An application to Second-Line Antiretroviral Therapy in India," MPRA Paper 60997, University Library of Munich, Germany.

  7. McCabe, C & Brazier, J & Gilks, P & Tsuchiya, A & Roberts, J & O'Hagan, A & Stevens, K, 2004. "Estimating population cardinal health state valuation models from individual ordinal (rank) health state preference data," MPRA Paper 29759, University Library of Munich, Germany.

    Cited by:

    1. Brazier, J, 2005. "Current state of the art in preference-based measures of health and avenues for further research," MPRA Paper 29762, University Library of Munich, Germany.

  8. McCabe, C & Stevens, K & Roberts, J & Brazier, JE, 2003. "Health state values for the HUI 2 descriptive system: results from a UK survey," MPRA Paper 29744, University Library of Munich, Germany.

    Cited by:

    1. Rowen, D & Brazier, J & Tsuchiya, A & Hernández, M & Ibbotson, R, 2009. "The simultaneous valuation of states from multiple instruments using ranking and VAS data: methods and preliminary results," MPRA Paper 29841, University Library of Munich, Germany.
    2. Musal, R. Muzaffer & Soyer, Refik & McCabe, Christopher & Kharroubi, Samer A., 2012. "Estimating the population utility function: A parametric Bayesian approach," European Journal of Operational Research, Elsevier, vol. 218(2), pages 538-547.
    3. Rowen, D & Brazier, J & Roberts, J, 2008. "Mapping SF-36 onto the EQ-5D index: how reliable is the relationship?," MPRA Paper 29831, University Library of Munich, Germany.
    4. Carolyn Czoski-Murray & David Meads & Richard Edlin & Claire Hulme & Claudi Gorecki & Jane Nixon & Christopher McCabe, 2014. "Constructing a utility algorithm for the pressure ulcer quality of life-utility instrument (PUQOL-UI)," Working Papers 1404, Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds.
    5. McCabe, C & Brazier, J & Gilks, P & Tsuchiya, A & Roberts, J & O'Hagan, A & Stevens, K, 2004. "Estimating population cardinal health state valuation models from individual ordinal (rank) health state preference data," MPRA Paper 29759, University Library of Munich, Germany.
    6. Christopher McCabe & Richard Edlin & David Meads & Chantelle Brown & Samer Kharroubi, 2013. "Constructing Indirect Utility Models: Some Observations on the Principles and Practice of Mapping to Obtain Health State Utilities," PharmacoEconomics, Springer, vol. 31(8), pages 635-641, August.
    7. Piérard, Emmanuelle, 2014. "The effect of physician supply on health status: Canadian evidence," Health Policy, Elsevier, vol. 118(1), pages 56-65.
    8. Brazier, John & Rowen, Donna & Tsuchiya, Aki & Yang, Yaling & Young, Tracy A., 2011. "The impact of adding an extra dimension to a preference-based measure," Social Science & Medicine, Elsevier, vol. 73(2), pages 245-253, July.
    9. Katherine Stevens, 2012. "Valuation of the Child Health Utility 9D Index," PharmacoEconomics, Springer, vol. 30(8), pages 729-747, August.
    10. Richard Edlin & Christopher McCabe & David Meads, 2013. "Assignment errors and the valuation of EQ-5D health states-do responses mean what we think they mean?," Working Papers 1304, Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds.

Articles

  1. Christopher McCabe & Richard Edlin & David Meads & Chantelle Brown & Samer Kharroubi, 2013. "Constructing Indirect Utility Models: Some Observations on the Principles and Practice of Mapping to Obtain Health State Utilities," PharmacoEconomics, Springer, vol. 31(8), pages 635-641, August.

    Cited by:

    1. Samer A Kharroubi & Richard Edlin & David Meads & Chantelle Browne & Julia Brown & Christopher McCabe, 2013. "Use of Bayesian Markov Chain Monte Carlo Methods to Estimate EQ-5D Utility Scores from Eortic QLQ Data in Myeloma for Use in Cost effectiveness Analysis," Working Papers 1308, Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds.

  2. Christopher McCabe & Richard Edlin & Peter Hall, 2013. "Navigating Time and Uncertainty in Health Technology Appraisal: Would a Map Help?," PharmacoEconomics, Springer, vol. 31(9), pages 731-737, September.
    See citations under working paper version above.
  3. Peter Hall & Christopher McCabe, 2013. "What Evidence Is There for the Reimbursement of Personalised Medicine?," PharmacoEconomics, Springer, vol. 31(3), pages 181-183, March.

    Cited by:

    1. Leopold, C. & Vogler, S. & Habl, C. & Mantel-Teeuwisse, A.K. & Espin, J., 2013. "Personalised medicine as a challenge for public pricing and reimbursement authorities – A survey among 27 European countries on the example of trastuzumab," Health Policy, Elsevier, vol. 113(3), pages 313-322.

  4. Musal, R. Muzaffer & Soyer, Refik & McCabe, Christopher & Kharroubi, Samer A., 2012. "Estimating the population utility function: A parametric Bayesian approach," European Journal of Operational Research, Elsevier, vol. 218(2), pages 538-547.

    Cited by:

    1. Bottomley, Paul A. & Doyle, John R., 2013. "Comparing the validity of numerical judgements elicited by direct rating and point allocation: Insights from objectively verifiable perceptual tasks," European Journal of Operational Research, Elsevier, vol. 228(1), pages 148-157.

  5. Stevens, Katherine & McCabe, Christopher & Brazier, John & Roberts, Jennifer, 2007. "Multi-attribute utility function or statistical inference models: A comparison of health state valuation models using the HUI2 health state classification system," Journal of Health Economics, Elsevier, vol. 26(5), pages 992-1002, September.

    Cited by:

    1. Anirban Basu & William Dale & Arthur Elstein & David Meltzer, 2009. "A linear index for predicting joint health-states utilities from single health-states utilities," Health Economics, John Wiley & Sons, Ltd., vol. 18(4), pages 403-419.
    2. John Brazier & Jennifer Roberts, 2006. "Methods for Developing Preference-based Measures of Health," Chapters,in: The Elgar Companion to Health Economics, chapter 35 Edward Elgar Publishing.
    3. Gang Chen & Julie Ratcliffe, 2015. "A Review of the Development and Application of Generic Multi-Attribute Utility Instruments for Paediatric Populations," PharmacoEconomics, Springer, vol. 33(10), pages 1013-1028, October.

  6. John Brazier & Christopher McCabe, 2007. "Is there a case for using visual analogue scale valuations in CUA' by Parkin and Devlin a response: 'yes there is a case, but what does it add to ordinal data?," Health Economics, John Wiley & Sons, Ltd., vol. 16(6), pages 645-647.

    Cited by:

    1. Claire Hulme & Richard Edlin, 2009. "Valuing health using visual analogue scales and rank data: does the visual analogue scale contain cardinal information?," Working Papers 0901, Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds.
    2. Juan Ramos-Goñi & Oliver Rivero-Arias & María Errea & Elly Stolk & Michael Herdman & Juan Cabasés, 2013. "Dealing with the health state ‘dead’ when using discrete choice experiments to obtain values for EQ-5D-5L heath states," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 33-42, July.

  7. McCabe, Christopher & Brazier, John & Gilks, Peter & Tsuchiya, Aki & Roberts, Jennifer & O'Hagan, Anthony & Stevens, Katherine, 2006. "Using rank data to estimate health state utility models," Journal of Health Economics, Elsevier, vol. 25(3), pages 418-431, May.

    Cited by:

    1. Bansback, Nick & Brazier, John & Tsuchiya, Aki & Anis, Aslam, 2012. "Using a discrete choice experiment to estimate health state utility values," Journal of Health Economics, Elsevier, vol. 31(1), pages 306-318.
    2. Claire Hulme & Richard Edlin, 2009. "Valuing health using visual analogue scales and rank data: does the visual analogue scale contain cardinal information?," Working Papers 0901, Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds.
    3. Rowen, D & Brazier, J & Tsuchiya, A & Hernández, M & Ibbotson, R, 2009. "The simultaneous valuation of states from multiple instruments using ranking and VAS data: methods and preliminary results," MPRA Paper 29841, University Library of Munich, Germany.
    4. Luciana Scalone & Peep Stalmeier & Silvano Milani & Paul Krabbe, 2015. "Values for health states with different life durations," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(9), pages 917-925, December.
    5. John Brazier & Christopher McCabe, 2007. "Is there a case for using visual analogue scale valuations in CUA' by Parkin and Devlin a response: 'yes there is a case, but what does it add to ordinal data?," Health Economics, John Wiley & Sons, Ltd., vol. 16(6), pages 645-647.
    6. Brazier, J & Rowen, D & Yang, Y & Tsuchiya, A, 2009. "Using rank and discrete choice data to estimate health state utility values on the QALY scale," MPRA Paper 29891, University Library of Munich, Germany.
    7. Ratcliffe, J & Brazier, J & Tsuchiya, A & Symonds, T & Brown, M, 2006. "Estimation of a preference based single index from the sexual quality of life questionnaire (SQOL) using ordinal data," MPRA Paper 29768, University Library of Munich, Germany.
    8. Paul F. M. Krabbe & Elly A. Stolk & Nancy J. Devlin & Feng Xie & Elise H. Quik & A. Simon Pickard, 2017. "Head-to-head comparison of health-state values derived by a probabilistic choice model and scores on a visual analogue scale," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(8), pages 967-977, November.
    9. John Brazier & Donna Rowen & Yaling Yang & Aki Tsuchiya, 2012. "Comparison of health state utility values derived using time trade-off, rank and discrete choice data anchored on the full health-dead scale," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(5), pages 575-587, October.
    10. Julie Ratcliffe & John Brazier & Aki Tsuchiya & Tara Symonds & Martin Brown, 2009. "Using DCE and ranking data to estimate cardinal values for health states for deriving a preference-based single index from the sexual quality of life questionnaire," Health Economics, John Wiley & Sons, Ltd., vol. 18(11), pages 1261-1276.
    11. Juan Ramos-Goñi & Oliver Rivero-Arias & María Errea & Elly Stolk & Michael Herdman & Juan Cabasés, 2013. "Dealing with the health state ‘dead’ when using discrete choice experiments to obtain values for EQ-5D-5L heath states," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 33-42, July.
    12. Julie Ratcliffe & Leah Couzner & Terry Flynn & Michael Sawyer & Katherine Stevens & John Brazier & Leonie Burgess, 2011. "Valuing child health utility 9D health states with a young adolescent sample," Applied Health Economics and Health Policy, Springer, vol. 9(1), pages 15-27, January.
    13. Stevens, K, 2010. "Valuation of the Child Health Utility Index 9D (CHU9D)," MPRA Paper 29938, University Library of Munich, Germany.
    14. Bansback, Nick & Brazier, John & Tsuchiya, Aki & Anis, Aslam, 2010. "Using a discrete choice experiment to estimate societal health state utility values," MPRA Paper 29933, University Library of Munich, Germany.
    15. Katherine Stevens, 2012. "Valuation of the Child Health Utility 9D Index," PharmacoEconomics, Springer, vol. 30(8), pages 729-747, August.
    16. Terry Flynn, 2010. "Using Conjoint Analysis and Choice Experiments to Estimate QALY Values," PharmacoEconomics, Springer, vol. 28(9), pages 711-722, September.

  8. Mark J. Sculpher & Karl Claxton & Mike Drummond & Chris McCabe, 2006. "Whither trial-based economic evaluation for health care decision making?," Health Economics, John Wiley & Sons, Ltd., vol. 15(7), pages 677-687.

    Cited by:

    1. Dyfrig Hughes & Joanna Charles & Dalia Dawoud & Rhiannon Tudor Edwards & Emily Holmes & Carys Jones & Paul Parham & Catrin Plumpton & Colin Ridyard & Huw Lloyd-Williams & Eifiona Wood & Seow Tien Yeo, 2016. "Conducting Economic Evaluations Alongside Randomised Trials: Current Methodological Issues and Novel Approaches," PharmacoEconomics, Springer, vol. 34(5), pages 447-461, May.
    2. Schulenburg J.-Matthias Graf von der & Vauth Christoph, 2007. "Nach welchen ökonomischen Methoden sollten Gesundheitsleistungen in Deutschland evaluiert werden? / According to Which Economic Methods Should Health Care Services Become Evaluated in Germany?," Journal of Economics and Statistics (Jahrbuecher fuer Nationaloekonomie und Statistik), De Gruyter, vol. 227(5-6), pages 787-806, October.
    3. Manca, A & Austin, P. C, 2008. "Using propensity score methods to analyse individual patient-level cost-effectiveness data from observational studies," Health, Econometrics and Data Group (HEDG) Working Papers 08/20, HEDG, c/o Department of Economics, University of York.
    4. Ulla Griffiths & Benedict Anigbogu & Kiran Nanchahal, 2012. "Economic evaluations of adult weight management interventions," Applied Health Economics and Health Policy, Springer, vol. 10(3), pages 145-162, May.
    5. Graves, Nicholas & Clare, Gina & Haines, Mary & Bird, Robert, 2010. "A policy case study of blood in Australia," Social Science & Medicine, Elsevier, vol. 71(9), pages 1677-1682, November.
    6. Brousselle, Astrid & Lessard, Chantale, 2011. "Economic evaluation to inform health care decision-making: Promise, pitfalls and a proposal for an alternative path," Social Science & Medicine, Elsevier, vol. 72(6), pages 832-839, March.
    7. Zafar Zafari & Kristian Thorlund & J. FitzGerald & Carlo Marra & Mohsen Sadatsafavi, 2014. "Network vs. Pairwise Meta-Analyses: A Case Study of the Impact of an Evidence-Synthesis Paradigm on Value of Information Outcomes," PharmacoEconomics, Springer, vol. 32(10), pages 995-1004, October.
    8. Edward Wilson, 2015. "A Practical Guide to Value of Information Analysis," PharmacoEconomics, Springer, vol. 33(2), pages 105-121, February.
    9. Edward Burn & Alexander D. Liddle & Thomas W. Hamilton & Sunil Pai & Hemant G. Pandit & David W. Murray & Rafael Pinedo-Villanueva, 2017. "Choosing Between Unicompartmental and Total Knee Replacement: What Can Economic Evaluations Tell Us? A Systematic Review," PharmacoEconomics - Open, Springer, vol. 1(4), pages 241-253, December.
    10. Renee Lévesque & Daniele Marcelli & Héloïse Cardinal & Marie-Line Caron & Muriel Grooteman & Michiel Bots & Peter Blankestijn & Menso Nubé & Aileen Grassmann & Bernard Canaud & Afschin Gandjour, 2015. "Cost-Effectiveness Analysis of High-Efficiency Hemodiafiltration Versus Low-Flux Hemodialysis Based on the Canadian Arm of the CONTRAST Study," Applied Health Economics and Health Policy, Springer, vol. 13(6), pages 647-659, December.
    11. Daisuke Goto & Ya-Chen Tina Shih & Pascal Lecomte & Melvin Olson & Chukwukadibia Udeze & Yujin Park & C. Daniel Mullins, 2017. "Regression-Based Approaches to Patient-Centered Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 35(7), pages 685-695, July.
    12. Andrew Briggs, 2012. "Statistical Methods for Cost-effectiveness Analysis Alongside Clinical Trials," Chapters,in: The Elgar Companion to Health Economics, Second Edition, chapter 50 Edward Elgar Publishing.
    13. Richard M. Nixon & David Wonderling & Richard D. Grieve, 2010. "Non-parametric methods for cost-effectiveness analysis: the central limit theorem and the bootstrap compared," Health Economics, John Wiley & Sons, Ltd., vol. 19(3), pages 316-333.
    14. Kerry Bell & Belen Corbacho & Sarah Ronaldson & Gerry Richardson & David Torgerson & Michael Robling, 2018. "The impact of pre and perinatal lifestyle factors on child long term health and social outcomes: a systematic review," Health Economics Review, Springer, vol. 8(1), pages 1-18, December.
    15. Alexander Thompson & Bruce Guthrie & Katherine Payne, 2016. "Do Pills Have No Ills? Capturing the Impact of Direct Treatment Disutility," PharmacoEconomics, Springer, vol. 34(4), pages 333-336, April.
    16. Christoffer Lilja Terjesen & Julia Kovaleva & Lars Ehlers, 2017. "Early Assessment of the Likely Cost Effectiveness of Single-Use Flexible Video Bronchoscopes," PharmacoEconomics - Open, Springer, vol. 1(2), pages 133-141, June.
    17. Lois G. Kim & Simon G. Thompson, 2010. "Uncertainty and validation of health economic decision models," Health Economics, John Wiley & Sons, Ltd., vol. 19(1), pages 43-55.
    18. J.- Graf v. d. Schulenburg & Christoph Vauth & Thomas Mittendorf & Wolfgang Greiner, 2007. "Methods for determining cost-benefit ratios for pharmaceuticals in Germany," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 8(1), pages 5-31, September.
    19. Karl Claxton & Mark Sculpher & Tony Culyer, 2007. "Mark versus Luke? Appropriate Methods for the Evaluation of Public Health Interventions," Working Papers 031cherp, Centre for Health Economics, University of York.
    20. Cynthia P. Iglesias & Alexander Thompson & Wolf H. Rogowski & Katherine Payne, 2016. "Reporting Guidelines for the Use of Expert Judgement in Model-Based Economic Evaluations," PharmacoEconomics, Springer, vol. 34(11), pages 1161-1172, November.
    21. Laura Bojke & Andrea Manca & Miqdad Asaria & Ronan Mahon & Shijie Ren & Stephen Palmer, 2017. "How to Appropriately Extrapolate Costs and Utilities in Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 35(8), pages 767-776, August.
    22. J. Caro & Jörgen Möller, 2014. "Decision-Analytic Models: Current Methodological Challenges," PharmacoEconomics, Springer, vol. 32(10), pages 943-950, October.
    23. Rob Anderson, 2010. "Systematic reviews of economic evaluations: utility or futility?," Health Economics, John Wiley & Sons, Ltd., vol. 19(3), pages 350-364.
    24. Samantha Husbands & Susan Jowett & Pelham Barton & Joanna Coast, 2017. "How Qualitative Methods Can be Used to Inform Model Development," PharmacoEconomics, Springer, vol. 35(6), pages 607-612, June.

  9. Christopher McCabe & Katherine Stevens & Jennifer Roberts & John Brazier, 2006. "Erratum to 'Health state values for the health utilities index mark 2 descriptive system: results from a UK valuation survey' Health Economics 2005; 14 (3): 231-244," Health Economics, John Wiley & Sons, Ltd., vol. 15(7), pages 761-761.

    Cited by:

    1. Stevens, K, 2010. "Valuation of the Child Health Utility Index 9D (CHU9D)," MPRA Paper 29938, University Library of Munich, Germany.

  10. Karl Claxton & Mark Sculpher & Anthony Culyer & Chris McCabe & Andrew Briggs & Ron Akehurst & Martin Buxton & John Brazier, 2006. "Discounting and cost-effectiveness in NICE - stepping back to sort out a confusion," Health Economics, John Wiley & Sons, Ltd., vol. 15(1), pages 1-4.

    Cited by:

    1. Hugh Gravelle & Werner Brouwer & Louis Niessen & Maarten Postma & Frans Rutten, 2007. "Discounting in economic evaluations: stepping forward towards optimal decision rules," Health Economics, John Wiley & Sons, Ltd., vol. 16(3), pages 307-317.
    2. van Baal, P.H. & Feenstra, T.L. & Polder, J.J. & Hoogenveen, R.T. & Brouwer, W., 2011. "Economic evaluation and the postponement of health care costs," Other publications TiSEM ee3d1a20-234a-46d7-8acd-d, Tilburg University, School of Economics and Management.
    3. M. Parouty & H. Le & D. Krooshof & M. Postma, 2014. "Differential Time Preferences for Money and Quality of Life," PharmacoEconomics, Springer, vol. 32(4), pages 411-419, April.
    4. Weatherly, Helen & Drummond, Michael & Claxton, Karl & Cookson, Richard & Ferguson, Brian & Godfrey, Christine & Rice, Nigel & Sculpher, Mark & Sowden, Amanda, 2009. "Methods for assessing the cost-effectiveness of public health interventions: Key challenges and recommendations," Health Policy, Elsevier, vol. 93(2-3), pages 85-92, December.
    5. van der Pol, Marjon & Cairns, John, 2008. "Comparison of two methods of eliciting time preference for future health states," Social Science & Medicine, Elsevier, vol. 67(5), pages 883-889, September.
    6. Kontodimopoulos, Nick & Niakas, Dimitris, 2008. "An estimate of lifelong costs and QALYs in renal replacement therapy based on patients' life expectancy," Health Policy, Elsevier, vol. 86(1), pages 85-96, April.
    7. Mike Paulden & Anthony J Culyer, 2010. "Does cost-effectiveness analysis discriminate against patients with short life expectancy? Matters of logic and matters of context," Working Papers 055cherp, Centre for Health Economics, University of York.
    8. Christopher McCabe & Richard Edlin & Peter Hall, 2013. "Navigating Time and Uncertainty in Health Technology Appraisal: Would a Map Help?," PharmacoEconomics, Springer, vol. 31(9), pages 731-737, September.
    9. Mike Paulden & Anthony J. Culyer, 2010. "Does Cost-Effectiveness Analysis Discriminate against Patients with Short Life Expectancy?," Working Paper series 41_10, Rimini Centre for Economic Analysis.
    10. Mareike Schad & Jürgen John, 2012. "Towards a social discount rate for the economic evaluation of health technologies in Germany: an exploratory analysis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(2), pages 127-144, April.
    11. Mike Paulden & James O’Mahony & Anthony Culyer & Christopher McCabe, 2014. "Some Inconsistencies in NICE’s Consideration of Social Values," PharmacoEconomics, Springer, vol. 32(11), pages 1043-1053, November.

  11. Katherine J. Stevens & Christopher J. McCabe & John E. Brazier, 2006. "Mapping between Visual Analogue Scale and Standard Gamble data; results from the UK Health Utilities Index 2 valuation survey," Health Economics, John Wiley & Sons, Ltd., vol. 15(5), pages 527-533.

    Cited by:

    1. Katherine Stevens & Christopher McCabe & John Brazier, 2007. "Response to Shmueli," Health Economics, John Wiley & Sons, Ltd., vol. 16(7), pages 759-761.

  12. Christopher McCabe & Katherine Stevens & Jennifer Roberts & John Brazier, 2005. "Health state values for the HUI 2 descriptive system: results from a UK survey," Health Economics, John Wiley & Sons, Ltd., vol. 14(3), pages 231-244.
    See citations under working paper version above.
  13. Karl Claxton & Mark Sculpher & Chris McCabe & Andrew Briggs & Ron Akehurst & Martin Buxton & John Brazier & Tony O'Hagan, 2005. "Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra," Health Economics, John Wiley & Sons, Ltd., vol. 14(4), pages 339-347.

    Cited by:

    1. Laura Bojke & Karl Claxton & Stephen Palmer & Mark Sculpher, 2006. "Defining and characterising structural uncertainty in decision analytic models," Working Papers 009cherp, Centre for Health Economics, University of York.
    2. A. E. Ades & Karl Claxton & Mark Sculpher, 2006. "Evidence synthesis, parameter correlation and probabilistic sensitivity analysis," Health Economics, John Wiley & Sons, Ltd., vol. 15(4), pages 373-381.
    3. Mark J. Sculpher & Karl Claxton & Mike Drummond & Chris McCabe, 2006. "Whither trial-based economic evaluation for health care decision making?," Health Economics, John Wiley & Sons, Ltd., vol. 15(7), pages 677-687.
    4. Lionel Perrier & Anne Lefranc & Philippe Quittet & Philippe Moreau & Carole Siani & Hervé Ghesquières & Fabrice Jardin & Bertrand Favier & Norbert Ifrah & Séverine Lissandre & David Pérol & Catherine , 2011. "Cost-effectiveness of Pegfilgrastim versus Filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma," Post-Print halshs-00628829, HAL.
    5. Torbjørn Wisløff & Gunhild Hagen & Vida Hamidi & Espen Movik & Marianne Klemp & Jan Olsen, 2014. "Estimating QALY Gains in Applied Studies: A Review of Cost-Utility Analyses Published in 2010," PharmacoEconomics, Springer, vol. 32(4), pages 367-375, April.
    6. McKenna, Claire & Chalabi, Zaid & Epstein, David & Claxton, Karl, 2010. "Budgetary policies and available actions: A generalisation of decision rules for allocation and research decisions," Journal of Health Economics, Elsevier, vol. 29(1), pages 170-181, January.
    7. Mattias Ekman & Peter Lindgren & Carolin Miltenburger & Genevieve Meier & Julie Locklear & Mary Chatterton, 2012. "Cost Effectiveness of Quetiapine in Patients with Acute Bipolar Depression and in Maintenance Treatment after an Acute Depressive Episode," PharmacoEconomics, Springer, vol. 30(6), pages 513-530, June.
    8. Dominic Tilden & Segundo Mariz & Gillies O’Bryan-Tear & Julia Bottomley & Alexander Diamantopoulos, 2007. "A Lifetime Modelled Economic Evaluation Comparing Pioglitazone and Rosiglitazone for the Treatment of Type 2 Diabetes Mellitus in the UK," PharmacoEconomics, Springer, vol. 25(1), pages 39-54, January.
    9. Bogdan Grigore & Jaime Peters & Christopher Hyde & Ken Stein, 2013. "Methods to Elicit Probability Distributions from Experts: A Systematic Review of Reported Practice in Health Technology Assessment," PharmacoEconomics, Springer, vol. 31(11), pages 991-1003, November.
    10. Matt Stevenson & Peter Selby, 2014. "Modelling the Cost Effectiveness of Interventions for Osteoporosis: Issues to Consider," PharmacoEconomics, Springer, vol. 32(8), pages 735-743, August.
    11. Marta Soares & Luísa Canto e Castro, 2012. "Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 30(12), pages 1101-1117, December.
    12. Fernando Antonanzas & Benoit Rive & Josep Badenas & Susana Gomez-Lus & Chantal Guilhaume, 2006. "Cost-effectiveness of memantine in community-based Alzheimer’s disease patients: an adaptation in Spain," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(2), pages 137-144, June.
    13. Anthony Newall & Mark Jit & Philippe Beutels, 2012. "Economic Evaluations of Childhood Influenza Vaccination," PharmacoEconomics, Springer, vol. 30(8), pages 647-660, August.
    14. Alan Brennan & Stephen E. Chick & Ruth Davies, 2006. "A taxonomy of model structures for economic evaluation of health technologies," Health Economics, John Wiley & Sons, Ltd., vol. 15(12), pages 1295-1310.
    15. Emma McIntosh, 2006. "Using Discrete Choice Experiments within a Cost-Benefit Analysis Framework," PharmacoEconomics, Springer, vol. 24(9), pages 855-868, September.
    16. Mohan V. Bala & Gary A. Zarkin & Josephine Mauskopf, 2008. "Presenting results of probabilistic sensitivity analysis: the incremental benefit curve," Health Economics, John Wiley & Sons, Ltd., vol. 17(3), pages 435-440.
    17. Anthony O'Hagan & Matt Stevenson & Jason Madan, 2007. "Monte Carlo probabilistic sensitivity analysis for patient level simulation models: efficient estimation of mean and variance using ANOVA," Health Economics, John Wiley & Sons, Ltd., vol. 16(10), pages 1009-1023.
    18. Yevgeniy Samyshkin & Robert Kotchie & Ann-Christin Mörk & Andrew Briggs & Eric Bateman, 2014. "Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 69-82, January.
    19. Marta O Soares & L Canto e Castro, 2010. "Simulation or cohort models? Continuous time simulation and discretized Markov models to estimate cost-effectiveness," Working Papers 056cherp, Centre for Health Economics, University of York.
    20. Adam J. N. Raymakers & John Mayo & Stephen Lam & J. Mark FitzGerald & David G. T. Whitehurst & Larry D. Lynd, 2016. "Cost-Effectiveness Analyses of Lung Cancer Screening Strategies Using Low-Dose Computed Tomography: a Systematic Review," Applied Health Economics and Health Policy, Springer, vol. 14(4), pages 409-418, August.
    21. Torbjørn Wisløff & Gunhild Hagen & Marianne Klemp, 2014. "Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation," PharmacoEconomics, Springer, vol. 32(6), pages 601-612, June.
    22. Laura Bojke & Bogdan Grigore & Dina Jankovic & Jaime Peters & Marta Soares & Ken Stein, 2017. "Informing Reimbursement Decisions Using Cost-Effectiveness Modelling: A Guide to the Process of Generating Elicited Priors to Capture Model Uncertainties," PharmacoEconomics, Springer, vol. 35(9), pages 867-877, September.
    23. Steven Edwards & Sarah Wordsworth & Mike Clarke, 2012. "Treating pneumonia in critical care in the United Kingdom following failure of initial antibiotic: a cost-utility analysis comparing meropenem with piperacillin/tazobactam," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(2), pages 181-192, April.
    24. Kurinchi Gurusamy & Edward Wilson & Andrew Burroughs & Brian Davidson, 2012. "Intra-operative vs pre-operative endoscopic sphincterotomy in patients with gallbladder and common bile duct stones," Applied Health Economics and Health Policy, Springer, vol. 10(1), pages 15-29, January.
    25. Karl Claxton & Stephen Palmer & Louise Longworth & Laura Bojke & Susan Griffin & Claire McKenna & Marta Soares & Eldon Spackman & Jihee Youn, 2011. "Uncertainty, evidence and irrecoverable costs: Informing approval, pricing and research decisions for health technologies," Working Papers 069cherp, Centre for Health Economics, University of York.
    26. Jagpreet Chhatwal & Tianhua He, 2015. "Economic Evaluations with Agent-Based Modelling: An Introduction," PharmacoEconomics, Springer, vol. 33(5), pages 423-433, May.

More information

Research fields, statistics, top rankings, if available.

Statistics

Access and download statistics for all items

Co-authorship network on CollEc

Featured entries

This author is featured on the following reading lists, publication compilations or Wikipedia entries:
  1. University of Alberta Economists (UAE)

NEP Fields

NEP is an announcement service for new working papers, with a weekly report in each of many fields. This author has had 5 papers announced in NEP. These are the fields, ordered by number of announcements, along with their dates. If the author is listed in the directory of specialists for this field, a link is also provided.
  1. NEP-HEA: Health Economics (4) 2013-11-02 2013-11-02 2013-11-02 2013-11-02
  2. NEP-UPT: Utility Models & Prospect Theory (2) 2013-11-02 2013-11-02

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.

To update listings or check citations waiting for approval, Christopher Joseph McCabe should log into the RePEc Author Service.

To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.

To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.

Please note that most corrections can take a couple of weeks to filter through the various RePEc services.

IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.